Systemic sclerosis & Raynaud's

Microvascular damage in autoimmune connective tissue diseases: a capillaroscopic analysis from 20 years of experience in a EULAR training and research referral centre for imaging

RMD OpenPublished Retrospective cohort study

Authors' conclusion

This large size sample of patients with CTDs, collected over 20 years of analysis, confirms the highest prevalence of specific capillaroscopic alterations in patients with SSc, DM and MCTD, when compared with other CTDs.

Study context

Population
Patients with Raynaud's phenomenon secondary to a CTD at first single nailfold videocapillaroscopy (NVC), 2001–2021
Participants
1,181 patients
Exposure
Capillaroscopic findings across connective tissue diseases (CTDs)
Outcome
Prevalence of morphological capillary findings on NVC (scleroderma and non-scleroderma patterns)
Follow-up
First single NVC
Methodological detailssingle-centre, EULAR referral centre
  • Single-centre
  • EULAR referral centre

Main finding

As reported in the abstract

Giant capillaries

P < 0.001 when comparing each rate vs the other CTDs

Observational data: associations, not effects.

Further findings

OutcomeValuesP value
Mean capillary countSSc, DM, MCTD (each) vs other CTDs · significantly lowerSSc mean 7.04 ± 0.18 capillaries/linear mm · DM mean 6.5 ± 0.75 capillaries/linear mm · MCTD mean 7.7 ± 2 capillaries/linear mmP < 0.001 for each rate vs the other CTDs
Non-specific abnormalities of capillary morphologySSc, MCTD, aPS (each) vs other CTDs · significantly more frequentSSc 48% · MCTD 41% · aPS 36%all p<0.001 vs each other CTDs

Original publication

Microvascular damage in autoimmune connective tissue diseases: a capillaroscopic analysis from 20 years of experience in a EULAR training and research referral centre for imaging. RMD Open. Published 14 July 2023. doi:10.1136/rmdopen-2023-003071

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.